Sinovac Biotech LTD Schedule 13D activist filings

1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited, and Dr. Jiaqiang Li have increased their beneficial ownership in Sinovac Biotech Ltd. to 32.3% while actively engaged in multiple ongoing legal disputes concerning corporate control and share validity.

SAIF Partners IV L.P. and YZ Healthcare L.P. have amended and restated their investment agreement concerning the sale of Sinovac Biotech Ltd. common shares, extending key option periods and clarifying terms.

Sinovac Biotech Ltd. has announced the formation of a new Board of Directors, with significant shareholder Weidong Yin accepting an appointment to the board and expressing intent to engage in corporate governance discussions to enhance shareholder value.

Advantech Capital and allied shareholders successfully elected new directors to Sinovac Biotech's board after a contested Special Meeting, overcoming an interim injunction.

SAIF Partners IV L.P. and its affiliates have filed an amended Schedule 13D for Sinovac Biotech Ltd., disclosing a 15% beneficial ownership stake, the formation of a new board of directors, and ongoing discussions with other shareholders to enhance corporate governance and shareholder value.

A U.S. District Court has issued a preliminary injunction against 1Globe Capital and its owner, Jiaqiang Li, for making materially misleading statements regarding Sinovac Biotech Ltd., coinciding with the election of a new board of directors supported by Vivo Capital.

1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited filed Amendment No. 6 to their Schedule 13D for Sinovac Biotech Ltd., correcting previous errors and providing updates on ongoing litigation regarding beneficial ownership and corporate governance.

1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited, led by Dr. Chiang Li, have voted their significant stake against proposals to remove and replace the current board of Sinovac Biotech Ltd., highlighting ongoing corporate governance disputes and litigation.

1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited, holding 32.3% of Sinovac Biotech Ltd. common shares, have formally declared their vote against proposals to remove and replace current board members at the upcoming Special Meeting.

Weidong Yin, a significant shareholder of Sinovac Biotech Ltd., has updated his Schedule 13D filing to disclose his nomination to the company's board of directors by SAIF Partners IV L.P. ahead of a special shareholder meeting.

SAIF Partners, a significant shareholder in Sinovac Biotech Ltd., has initiated a proxy solicitation to remove current board members and elect a new slate of directors, aiming to enhance shareholder value, resume stock trading, and increase dividend distributions.

Vivo Capital, an approximately 8% shareholder in Sinovac Biotech, has issued a letter to shareholders refuting the Board's claims, highlighting a severe corporate governance crisis, auditor resignation, and potential NASDAQ delisting.

SAIF Partners IV L.P. has filed an Amendment No. 17 to its Schedule 13D, extending the Right of First Refusal and Put Option periods with YZ Healthcare L.P. concerning its 15% stake in Sinovac Biotech Ltd. until November 25, 2025.

Weidong Yin, a significant shareholder and director of Sinovac Biotech Ltd., has disclosed a requisition by SAIF Partners IV L.P. to convene a special shareholders' meeting for the purpose of nominating new board members, including Yin himself, though no cooperation agreement has been reached.

SAIF Partners IV L.P., a significant shareholder in Sinovac Biotech LTD, has formally demanded a special shareholders' meeting to remove three current directors and elect ten new nominees to the company's board.

Vivo Capital has filed multiple lawsuits against Sinovac Biotech Ltd.'s new Board of Directors, alleging value-destructive actions and a corporate governance crisis that led to the resignation of the company's independent auditor.

Advantech Capital and affiliated entities are challenging Sinovac Biotech's implied intent to invalidate their shares and exclude them from a cash dividend, joining an arbitration to protect their 8.14% stake.

A group of investment entities, including Advantech Capital L.P. and Prime Success, L.P., have filed a Schedule 13D indicating their collective beneficial ownership of 8.14% of Sinovac Biotech Ltd. and their intent to defend their investment amidst recent board changes and a shareholder requisition.

Sinovac Biotech Ltd.'s President and CEO, Weidong Yin, has increased his beneficial ownership to 8.85% of common shares, coinciding with a requisition from SAIF Partners IV L.P. to nominate him and others to the Board.

Vivo Capital, a significant shareholder in Sinovac Biotech Ltd., has initiated arbitration against the company following the exclusion of its board designee and implied threats to invalidate a 2018 private placement.

SAIF Partners IV L.P., holding a 15% stake in Sinovac Biotech Ltd., has formally requisitioned a special shareholders' meeting to remove three current directors and elect ten new nominees, including the company's CEO, in a significant corporate governance challenge.

SAIF Partners IV L.P. and its affiliates have filed an Amendment No. 14 to their Schedule 13D, extending the Right of First Refusal and Put Option periods related to their investment agreement with YZ Healthcare L.P. concerning Sinovac Biotech Ltd. shares.